Genetic developmental defect of the eye

Genetic developmental defect of the eye is a broad grouping category (Orphanet code 183557) that encompasses a wide range of rare inherited conditions in which the eye does not develop normally during embryonic or fetal life. These disorders affect the structure and function of the eye and its associated tissues, including the globe, lens, cornea, iris, retina, optic nerve, and surrounding orbital structures. Clinical manifestations vary widely depending on the specific condition and may include microphthalmia (abnormally small eyes), anophthalmia (absence of one or both eyes), coloboma (gaps in eye structures), anterior segment dysgenesis, congenital cataracts, congenital glaucoma, persistent fetal vasculature, and various forms of retinal dysplasia. These defects can occur in isolation or as part of broader syndromic conditions affecting multiple organ systems. Because this category represents a group of disorders rather than a single disease entity, the underlying genetic causes are highly heterogeneous. Mutations in numerous genes involved in eye development — such as PAX6, SOX2, OTX2, VSX2, RAX, FOXE3, PITX2, PITX3, MAF, and many others — have been implicated. Inheritance patterns vary across the specific conditions and may be autosomal dominant, autosomal recessive, or X-linked. Some cases arise from de novo mutations. Chromosomal abnormalities and copy number variants can also be responsible. The severity of visual impairment ranges from mild reduction in visual acuity to complete blindness, depending on the specific structures affected and the degree of developmental disruption. Management is multidisciplinary and may include ophthalmological surveillance, corrective lenses, surgical interventions (such as cataract removal, glaucoma surgery, or orbital implants for anophthalmia), and supportive therapies including low-vision rehabilitation and early developmental support. Genetic counseling is recommended for affected individuals and families to clarify the specific diagnosis, inheritance pattern, and recurrence risk. Currently, no gene therapies are broadly available for most conditions in this group, though research is ongoing for select subtypes.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic developmental defect of the eye